Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
AI In Clinical Trials Market Revenue Outlook: What CAGR Is Expected Through 2030?
The AI in clinical trials market has experienced significant expansion in recent years. This market is projected to increase from $9.16 billion in 2025 to $13.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 42.8%. The growth observed in the past can be attributed to factors like the increasing complexity of clinical trials, greater R&D expenditure, the imperative for swifter drug development, an increase in clinical data volumes, and the inherent limitations of traditional trial methods.
The AI in clinical trials market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $54.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 43.0%. This expansion over the forecast period can be attributed to the rise of decentralized clinical trials, greater use of real-world evidence, the advancement of precision medicine, increasing regulatory acceptance of AI tools, and progress in healthcare analytics. Prominent trends for the forecast period include AI-driven patient recruitment, predictive modeling for trial outcomes, automated clinical data analysis, integration of remote patient monitoring, and the adoption of adaptive trial designs.
Download A Free Sample Report For Comprehensive Market Insights:
AI In Clinical Trials Market Growth Momentum: Which Factors Are Influencing Demand?
The increasing occurrence of chronic and infectious diseases is predicted to accelerate the expansion of the AI in clinical trials market in the future. A chronic disease is characterized as an illness that endures for three months or longer and may worsen over time. Artificial intelligence in clinical trials proves beneficial in creating various medications for addressing chronic diseases. For instance, in August 2024, the Macmillan Cancer Support, a UK-based organization, reported that in 2024, more than 3 million people in the UK are living with cancer. This figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the growing incidences of chronic and infectious diseases are propelling the growth of the AI in the clinical trials market.
AI In Clinical Trials Market Segment Analysis: What Are The Major Market Categories?
The AI in clinical trials market covered in this report is segmented –
1) By Offering: Software, Services
2) By Process: Trial Design, Patient Selection, Site Selection, Patient Monitoring
3) By Technology: Machine Learning, Deep Learning, Supervised Learning, Other Technologies
4) By Application: Oncology, Neurological Diseases And Condition, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Immunology Diseases, Other Applications
5) By End-User: Pharmaceuticals And Biotechnology Companies, Contract Research Organizations, Other End-Users
Subsegments:
1) By Software: Clinical Trial Management Systems (CTMS), Data Analytics Software, Predictive Analytics Tools, Patient Recruitment And Retention Software, Real-World Evidence Platforms
2) By Services: Consulting Services, Data Management And Analysis Services, Training And Support Services, Regulatory Compliance Services
AI In Clinical Trials Market Industry Trends: What Changes Are Reshaping Demand?
Leading companies operating within the AI in clinical trials market are adopting a strategic partnership approach to provide research tools and operational efficiencies, resulting in improved schedules and increased patient recruitment. Strategic partnerships refer to a method where companies capitalize on each other’s strengths and assets to attain mutual benefits and successful outcomes. For instance, in February 2023, a US-based pharmaceutical commercial company formed an alliance with Haystack Health, a US-based software development company. Through this collaboration, their goal is to leverage AI and Natural Language Processing (NLP) to accelerate clinical trials, enhance patient recruitment, and lower the screen failure rate by utilizing clinical AI and pre-screening services, which can be costly in terms of both time and money.
AI In Clinical Trials Market Leading Companies Driving Competitive Growth
Major companies operating in the AI in clinical trials market are ConcertAI Inc.; Owkin Inc.; AiCure Technologies Inc.; Ardigen S.A.; Unlearn.AI Inc.; PathAI Inc.; Exscientia plc; VeriSIM Life Inc.; Envisagenics Inc.; NURITAS Limited; BioSymetrics Inc.; Trials.AI Inc.; IQVIA Holdings Inc.; Euretos B.V.; Saama Technologies LLC; Deep 6 AI Inc.; Medidata Solutions Inc.; Antidote Technologies Inc.; Castor EDC B.V.; TrialSpark Inc.; Phesi S.A.; CluePoints NV
Access The Complete AI In Clinical Trials Market Report:
AI In Clinical Trials Market Geographic Distribution And Regional Opportunities
North America was the largest region in the AI in clinical trials market in 2025. The regions covered in the AI in clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
